TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05922423

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
Study: NCT05238896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet [Olumiant]
Description: Baricitinib 4 mg/d oral route for 42 days
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05238896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT04742153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT06446323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 ml dose of sucrose
Description: Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 ml dose of sucrose
Description: Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
Study: NCT05405257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
Study: NCT06506513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: High-intensity interval training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: Moderate intensity exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise training
Description: Low intensity exercise training
Study: NCT05336760

Intervention type: DIAGNOSTIC_TEST
Intervention: Iowa Oral Performance Instrument (IOPI)
Description: IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mann Assessment of Swallowing Ability (MASA)
Description: MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory function measurements
Description: Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
Study: NCT05293496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
Study: NCT05553548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biologically oriented alveolar ridge preservation
Description: xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenogenic bone graft in entire (apico-coronal) extension
Description: xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
Study: NCT04955145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RUTA C 60
Description: Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RUTA C 60
Description: Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT05678959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab 120 mg
Description: 1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Description: 2 injections of 1.0 mL ligelizumab
Study: NCT05293496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Study: NCT06103799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model-based continuity of care
Description: The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
Study: NCT05293496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lorigerlimab
Description: Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Study: NCT03817593

Intervention type: OTHER
Intervention: Transcendental Meditation (TM)
Description: Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
Study: NCT05639543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INT-787
Description: Blinded Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05896982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual with information support
Description: Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual with supportive coaching
Description: Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual with information support and supportive coaching
Description: This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
Study: NCT04904653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No sealant (liquid, gel or patch) + suction drain
Study: NCT05654519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG/LFCN and QL Blocks
Description: Bupivacaine 0.25% injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG/LFCN and QL Blocks
Description: Bupivacaine 0.25% injection
Study: NCT05581485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated Laryngomicrosurgery
Description: Non-intubated LMS was performed with assistance of Optiflow(HFNO).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-intubated Laryngomicrosurgery
Description: Non-intubated LMS was performed with assistance of Optiflow(HFNO).
Study: NCT05139862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
Study: NCT06297096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg s.c./week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Study: NCT06099743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Intervention manual and six one-on-one coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Intervention manual and six one-on-one coaching sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual supportive care
Description: Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.
Study: NCT04545593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Minds Strong Bodies Enhanced
Description: The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
Study: NCT04314973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Pelvis Orthosis
Description: Walking with the robotic device providing the assistive protocol.
Study: NCT05703347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fixed sleep goal
Description: Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
Study: NCT04353661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin will be administered orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HP xenon (¹²⁹XE)
Description: HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HP xenon (¹²⁹XE)
Description: HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HP xenon (¹²⁹XE)
Description: HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
Study: NCT05910736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medicare AWV Practice Redesign Toolkit
Description: Electronic health record-based tools coupled with practice redesign strategies and approaches
Study: NCT05703347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
Study: NCT04314973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercises
Description: Walking exercises without wearing the robotic device.
Study: NCT05703347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging without virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital sleep health messaging with virtual study visit
Description: All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
Study: NCT04841499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
Description: take 2 capsules orally each day for 7 days
Study: NCT05181085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NST 6179
Description: orally administered, fully synthetic medium chain fatty acid (MCFA) analogue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive analogue
Study: NCT06548971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
Study: NCT06488573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: 7 individual sessions + 8 small group sessions
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211216
Description: Flavor variant P1211216 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213416
Description: Flavor variant P1213416 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213716
Description: Flavor variant P1213716 of a 1.5% nicotine ENDS product
Study: NCT06548971

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best medical management
Description: Patients in both groups will receive the best medical management according to the guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: Patients in both groups will receive the best medical management according to the guidelines.